JP2003524592A - 持続放出薬物製剤 - Google Patents
持続放出薬物製剤Info
- Publication number
- JP2003524592A JP2003524592A JP2000557816A JP2000557816A JP2003524592A JP 2003524592 A JP2003524592 A JP 2003524592A JP 2000557816 A JP2000557816 A JP 2000557816A JP 2000557816 A JP2000557816 A JP 2000557816A JP 2003524592 A JP2003524592 A JP 2003524592A
- Authority
- JP
- Japan
- Prior art keywords
- hydrochloride
- acid
- therapeutic agent
- coating
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 38
- 238000013268 sustained release Methods 0.000 title claims abstract description 36
- 239000013583 drug formulation Substances 0.000 title claims 2
- 239000003814 drug Substances 0.000 claims abstract description 151
- 238000000576 coating method Methods 0.000 claims abstract description 79
- 239000011248 coating agent Substances 0.000 claims abstract description 76
- 239000002702 enteric coating Substances 0.000 claims abstract description 60
- 238000009505 enteric coating Methods 0.000 claims abstract description 60
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 claims abstract description 44
- 229960002790 phenytoin sodium Drugs 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 230000001419 dependent effect Effects 0.000 claims abstract description 15
- 239000011253 protective coating Substances 0.000 claims abstract description 15
- 229940124597 therapeutic agent Drugs 0.000 claims description 65
- 239000000203 mixture Substances 0.000 claims description 46
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 45
- 229960002036 phenytoin Drugs 0.000 claims description 42
- 229920000642 polymer Polymers 0.000 claims description 37
- 238000009472 formulation Methods 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 30
- 239000002253 acid Substances 0.000 claims description 27
- 239000000725 suspension Substances 0.000 claims description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 23
- 239000006186 oral dosage form Substances 0.000 claims description 18
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 15
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 14
- 238000005507 spraying Methods 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 10
- 239000007884 disintegrant Substances 0.000 claims description 10
- 229920001249 ethyl cellulose Polymers 0.000 claims description 10
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 239000001856 Ethyl cellulose Substances 0.000 claims description 9
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 210000004051 gastric juice Anatomy 0.000 claims description 9
- 239000008188 pellet Substances 0.000 claims description 9
- 239000004014 plasticizer Substances 0.000 claims description 9
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 9
- DYWNLSQWJMTVGJ-KUSKTZOESA-N Phenylpropanolamine hydrochloride Chemical compound Cl.C[C@H](N)[C@H](O)C1=CC=CC=C1 DYWNLSQWJMTVGJ-KUSKTZOESA-N 0.000 claims description 8
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 claims description 8
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 8
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 8
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 8
- 229960002305 phenylpropanolamine hydrochloride Drugs 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 239000001530 fumaric acid Substances 0.000 claims description 7
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000011007 phosphoric acid Nutrition 0.000 claims description 6
- KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 150000007513 acids Chemical class 0.000 claims description 5
- ZQDJSWUEGOYDGT-UHFFFAOYSA-N bromazine hydrochloride Chemical compound [Cl-].C=1C=C(Br)C=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 ZQDJSWUEGOYDGT-UHFFFAOYSA-N 0.000 claims description 5
- CGDDQFMPGMYYQP-UHFFFAOYSA-N disopyramide phosphate Chemical compound OP(O)(O)=O.C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 CGDDQFMPGMYYQP-UHFFFAOYSA-N 0.000 claims description 5
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol hydrochloride Natural products C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 claims description 4
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- 229940068716 bromodiphenhydramine hydrochloride Drugs 0.000 claims description 4
- 229960004993 dimenhydrinate Drugs 0.000 claims description 4
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 claims description 4
- 229960001863 disopyramide phosphate Drugs 0.000 claims description 4
- 229960005008 doxylamine succinate Drugs 0.000 claims description 4
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims description 4
- 229960003220 hydroxyzine hydrochloride Drugs 0.000 claims description 4
- 229940070023 iproniazide Drugs 0.000 claims description 4
- 238000011068 loading method Methods 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 239000011976 maleic acid Substances 0.000 claims description 4
- 239000001630 malic acid Substances 0.000 claims description 4
- 235000011090 malic acid Nutrition 0.000 claims description 4
- KRPAJLYSLFNDOA-UHFFFAOYSA-N mephenesin carbamate Chemical compound CC1=CC=CC=C1OCC(O)COC(N)=O KRPAJLYSLFNDOA-UHFFFAOYSA-N 0.000 claims description 4
- 229950006838 mephenesin carbamate Drugs 0.000 claims description 4
- IZRPKIZLIFYYKR-UHFFFAOYSA-N phenyltoloxamine Chemical compound CN(C)CCOC1=CC=CC=C1CC1=CC=CC=C1 IZRPKIZLIFYYKR-UHFFFAOYSA-N 0.000 claims description 4
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 claims description 4
- 229960002244 promethazine hydrochloride Drugs 0.000 claims description 4
- 229960004604 propranolol hydrochloride Drugs 0.000 claims description 4
- XYITYKDGJLHYPW-UHFFFAOYSA-M sodium 2-iodohippurate Chemical compound [Na+].[O-]C(=O)CNC(=O)C1=CC=CC=C1I XYITYKDGJLHYPW-UHFFFAOYSA-M 0.000 claims description 4
- AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 claims description 4
- 239000004925 Acrylic resin Substances 0.000 claims description 3
- 229920000178 Acrylic resin Polymers 0.000 claims description 3
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 claims description 3
- 229920001800 Shellac Polymers 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 235000011054 acetic acid Nutrition 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 239000007900 aqueous suspension Substances 0.000 claims description 3
- 235000010233 benzoic acid Nutrition 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- -1 defoamers Substances 0.000 claims description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 3
- 235000011087 fumaric acid Nutrition 0.000 claims description 3
- 235000011167 hydrochloric acid Nutrition 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 235000006408 oxalic acid Nutrition 0.000 claims description 3
- 235000019260 propionic acid Nutrition 0.000 claims description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 3
- 239000004208 shellac Substances 0.000 claims description 3
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 3
- 229940113147 shellac Drugs 0.000 claims description 3
- 235000013874 shellac Nutrition 0.000 claims description 3
- 239000004334 sorbic acid Substances 0.000 claims description 3
- 235000010199 sorbic acid Nutrition 0.000 claims description 3
- 229940075582 sorbic acid Drugs 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- ODBLHEXUDAPZAU-UHFFFAOYSA-N threo-D-isocitric acid Natural products OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 claims description 3
- 239000001993 wax Substances 0.000 claims description 2
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 claims 6
- 229960000436 phendimetrazine Drugs 0.000 claims 6
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 claims 3
- NYMGNSNKLVNMIA-UHFFFAOYSA-N Iproniazid Chemical compound CC(C)NNC(=O)C1=CC=NC=C1 NYMGNSNKLVNMIA-UHFFFAOYSA-N 0.000 claims 3
- 239000004141 Sodium laurylsulphate Substances 0.000 claims 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 3
- 229940046978 chlorpheniramine maleate Drugs 0.000 claims 3
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 claims 3
- 229940098895 maleic acid Drugs 0.000 claims 3
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 claims 3
- 229960002532 methamphetamine hydrochloride Drugs 0.000 claims 3
- 229960001526 phenyltoloxamine Drugs 0.000 claims 3
- 229960000340 thiopental sodium Drugs 0.000 claims 3
- 229940079593 drug Drugs 0.000 abstract description 82
- 239000002552 dosage form Substances 0.000 abstract description 30
- 210000002784 stomach Anatomy 0.000 abstract description 23
- 239000004480 active ingredient Substances 0.000 abstract description 20
- 238000012377 drug delivery Methods 0.000 abstract description 9
- 239000000243 solution Substances 0.000 description 20
- 238000010521 absorption reaction Methods 0.000 description 19
- 239000011324 bead Substances 0.000 description 18
- 239000003094 microcapsule Substances 0.000 description 17
- 230000036470 plasma concentration Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 12
- 239000013543 active substance Substances 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 239000002775 capsule Substances 0.000 description 10
- 210000000936 intestine Anatomy 0.000 description 10
- 210000001072 colon Anatomy 0.000 description 9
- 230000003111 delayed effect Effects 0.000 description 9
- 210000002429 large intestine Anatomy 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 8
- 229960004667 ethyl cellulose Drugs 0.000 description 8
- 230000002378 acidificating effect Effects 0.000 description 7
- 239000001961 anticonvulsive agent Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 210000000813 small intestine Anatomy 0.000 description 7
- 229920003134 Eudragit® polymer Polymers 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000012530 fluid Substances 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 102220570135 Histone PARylation factor 1_L30D_mutation Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920003149 Eudragit® E 100 Polymers 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000003556 anti-epileptic effect Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 3
- 229960000604 valproic acid Drugs 0.000 description 3
- 229920003137 Eudragit® S polymer Polymers 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 239000006057 Non-nutritive feed additive Substances 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOROEVAWQLGPFQ-UHFFFAOYSA-N 1-benzhydryl-4-methylpiperazine;2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 JOROEVAWQLGPFQ-UHFFFAOYSA-N 0.000 description 1
- NFLLKCVHYJRNRH-UHFFFAOYSA-N 8-chloro-1,3-dimethyl-7H-purine-2,6-dione 2-(diphenylmethyl)oxy-N,N-dimethylethanamine Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Cl)=N2.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 NFLLKCVHYJRNRH-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100028675 DNA polymerase subunit gamma-2, mitochondrial Human genes 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 239000004908 Emulsion polymer Substances 0.000 description 1
- 241001005836 Euchloe ausonia Species 0.000 description 1
- 229920003139 Eudragit® L 100 Polymers 0.000 description 1
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 1
- 229920003141 Eudragit® S 100 Polymers 0.000 description 1
- 101100321670 Fagopyrum esculentum FA18 gene Proteins 0.000 description 1
- 101000837415 Homo sapiens DNA polymerase subunit gamma-2, mitochondrial Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 241000102542 Kara Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 101001094026 Synechocystis sp. (strain PCC 6803 / Kazusa) Phasin PhaP Proteins 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 229940088007 benadryl Drugs 0.000 description 1
- 238000011021 bench scale process Methods 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 229960000428 carbinoxamine Drugs 0.000 description 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
- GVNWHCVWDRNXAZ-BTJKTKAUSA-N carbinoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 GVNWHCVWDRNXAZ-BTJKTKAUSA-N 0.000 description 1
- 229940088029 cardizem Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 241000902900 cellular organisms Species 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940064790 dilantin Drugs 0.000 description 1
- HDRXZJPWHTXQRI-BHDTVMLSSA-N diltiazem hydrochloride Chemical compound [Cl-].C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CC[NH+](C)C)C2=CC=CC=C2S1 HDRXZJPWHTXQRI-BHDTVMLSSA-N 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- MZNZKBJIWPGRID-UHFFFAOYSA-N diphenylphosphorylmethyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)CP(C=1C=CC=CC=1)C1=CC=CC=C1 MZNZKBJIWPGRID-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940099182 dramamine Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229960004842 ephedrine sulfate Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 150000004673 fluoride salts Chemical class 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940095990 inderal Drugs 0.000 description 1
- 230000000053 inderal effect Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 229940063647 marezine Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 229940088938 norpace Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229940107333 phenergan Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 229940074977 phenytoin oral suspension Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- YPDVTKJXVHYWFY-UHFFFAOYSA-N phosphoric acid;n'-propan-2-ylpyridine-4-carbohydrazide Chemical compound OP(O)(O)=O.CC(C)NNC(=O)C1=CC=NC=C1 YPDVTKJXVHYWFY-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/111,188 US5968554A (en) | 1998-07-07 | 1998-07-07 | Sustained release pharmaceutical preparation |
| US09/111,188 | 1998-07-07 | ||
| US09/338,716 | 1999-06-23 | ||
| US09/338,716 US6312728B1 (en) | 1998-07-07 | 1999-06-23 | Sustained release pharmaceutical preparation |
| PCT/US1999/014204 WO2000001369A1 (en) | 1998-07-07 | 1999-06-25 | Sustained release pharmaceutical preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003524592A true JP2003524592A (ja) | 2003-08-19 |
| JP2003524592A5 JP2003524592A5 (enExample) | 2006-01-05 |
Family
ID=26808709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000557816A Pending JP2003524592A (ja) | 1998-07-07 | 1999-06-25 | 持続放出薬物製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6312728B1 (enExample) |
| EP (1) | EP1094790B9 (enExample) |
| JP (1) | JP2003524592A (enExample) |
| AT (1) | ATE274344T1 (enExample) |
| AU (1) | AU5084299A (enExample) |
| CA (1) | CA2337046C (enExample) |
| DE (1) | DE69919713T2 (enExample) |
| ES (1) | ES2226412T3 (enExample) |
| IL (1) | IL140761A0 (enExample) |
| WO (1) | WO2000001369A1 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007507491A (ja) * | 2003-09-29 | 2007-03-29 | シージェー コーポレーション | 徐放性製剤 |
| JP2007519741A (ja) * | 2004-01-29 | 2007-07-19 | ヤマノウチ・ファーマ・テクノロジーズ・インク | 胃腸特異的複数薬物放出システム |
| JP2008509193A (ja) * | 2004-08-13 | 2008-03-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | プラミペキソール又はその薬学的に許容しうる塩を含有する徐放性ペレット製剤、その製法及び使用 |
| KR101443943B1 (ko) * | 2007-05-07 | 2014-10-07 | 에보니크 룀 게엠베하 | 가속된 약물 방출을 갖는 장용 코팅을 포함하는 고체 투여 형태 |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9803871D0 (sv) * | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
| US20030068356A1 (en) * | 2001-07-10 | 2003-04-10 | Pather S. Indiran | Sequential drug delivery systems |
| US6572889B1 (en) | 2002-03-07 | 2003-06-03 | Noveon Ip Holdings Corp. | Controlled release solid dosage carbamazepine formulations |
| US20040043067A1 (en) * | 2002-06-19 | 2004-03-04 | Salamone Joseph C. | Fluorosiloxane matrix controlled diffusion drug delivery systems |
| MY142204A (en) | 2002-07-25 | 2010-10-29 | Pharmacia Corp | Pramipexole once-daily dosage form |
| MXPA05004648A (es) * | 2002-10-30 | 2005-06-08 | Pharmacia Corp | Comprimidos orales de liberacion extendida y procedimientos de preparacion y uso de los mismos. |
| US7988993B2 (en) * | 2002-12-09 | 2011-08-02 | Andrx Pharmaceuticals, Inc. | Oral controlled release dosage form |
| US20040253293A1 (en) * | 2003-06-16 | 2004-12-16 | Afshin Shafiee | Rate controlled release of a pharmaceutical agent in a biodegradable device |
| US7712288B2 (en) * | 2004-05-28 | 2010-05-11 | Narayanan Ramasubramanian | Unified ingestion package and process for patient compliance with prescribed medication regimen |
| US9592197B2 (en) * | 2004-12-16 | 2017-03-14 | Sovereign Pharmaceuticals, Llc | Dosage form containing diphenhydramine and another drug |
| US20070003622A1 (en) * | 2004-12-16 | 2007-01-04 | Sovereign Pharmaceuticals, Ltd. | Diphenhydramine containing dosage form |
| US20060034910A1 (en) * | 2004-08-09 | 2006-02-16 | Sanjay Patel | Pharmaceutical composition for extended release of phenytoin sodium |
| KR101052436B1 (ko) | 2004-08-13 | 2011-07-29 | 베링거 인겔하임 인터내셔날 게엠베하 | 프라미펙솔 또는 약제학적으로 허용되는 이의 염을함유하는 연장 방출형 정제 제형, 이의 제조방법 및 이의용도 |
| US20060134175A1 (en) * | 2004-12-22 | 2006-06-22 | Stephen Bartels | Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use |
| US7529255B2 (en) * | 2005-04-21 | 2009-05-05 | Microsoft Corporation | Peer-to-peer multicasting using multiple transport protocols |
| MX2008010322A (es) | 2006-02-13 | 2009-03-05 | Vanda Pharmaceuticals Inc | Formulaciones de dosificacion estable de imidazolilalquil-piridina s. |
| JP5228359B2 (ja) * | 2007-04-12 | 2013-07-03 | ニプロ株式会社 | 主薬粒子及びその製造方法ならびに口腔内崩壊錠 |
| NZ585923A (en) | 2007-12-13 | 2012-09-28 | Vanda Pharmaceuticals Inc | Use of 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-benzoic acid for treating a condition that is mediated by a 5-HT2A receptor |
| EP2222301B1 (en) * | 2007-12-13 | 2014-10-08 | Vanda Pharmaceuticals Inc. | Method and composition for treating an alpha adrenoceptor-mediated condition |
| US20090214665A1 (en) * | 2008-02-26 | 2009-08-27 | Lai Felix S | Controlled Release Muscarinic Receptor Antagonist Formulation |
| US8663671B2 (en) * | 2009-11-05 | 2014-03-04 | Philip Morris Usa Inc. | Methods and compositions for producing hydrogel capsules coated for low permeability and physical integrity |
| US8999393B1 (en) | 2013-01-09 | 2015-04-07 | Edgemont Pharmaceuticals Llc | Sustained release formulations of lorazepam |
| KR20220128362A (ko) | 2019-12-27 | 2022-09-20 | 에벨로 바이오사이언시즈, 인크. | 박테리아 및 미생물 세포외 소포체를 함유하는 고체 투여 형태 |
| TW202140051A (zh) | 2020-01-17 | 2021-11-01 | 美商艾弗洛生物科技股份有限公司 | 具有改善的崩散譜之固體劑型 |
| US20230190831A1 (en) | 2020-04-17 | 2023-06-22 | Evelo Biosciences, Inc. | Solid dosage forms with improved disintegration profiles |
| CA3192766A1 (en) | 2020-09-18 | 2022-03-24 | Syed Altaf | Solid dosage forms of bacteria |
| JP2023548834A (ja) | 2020-10-29 | 2023-11-21 | エヴェロ バイオサイエンシズ，インコーポレーテッド | スピルリナ構成要素を含む組成物 |
| JP2024501481A (ja) | 2020-12-14 | 2024-01-12 | エヴェロ バイオサイエンシズ，インコーポレーテッド | 細胞外小胞調製物 |
| WO2022140396A1 (en) | 2020-12-22 | 2022-06-30 | Evelo Biosciences, Inc. | Compositions comprising animal hemoglobin |
| EP4284400A1 (en) | 2021-01-26 | 2023-12-06 | Evelo Biosciences, Inc. | Prevotella extracellular vesicle preparations |
| US20240148797A1 (en) | 2021-02-26 | 2024-05-09 | Evelo Biosciences, Inc. | Compositions and methods for reducing cytokine expression |
| TW202302125A (zh) | 2021-03-05 | 2023-01-16 | 美商艾弗洛生物科技股份有限公司 | 固體劑型 |
| EP4319723A1 (en) | 2021-04-08 | 2024-02-14 | Evelo Biosciences, Inc. | Pharmaceutical composition containing bacteria |
| WO2022221183A1 (en) | 2021-04-12 | 2022-10-20 | Evelo Biosciences, Inc. | Fournierella extracellular vesicle preparations |
| WO2022251166A2 (en) | 2021-05-25 | 2022-12-01 | Evelo Biosciences, Inc. | Bacterial compositions comprising soy hemoglobin |
| KR20240093504A (ko) | 2021-09-24 | 2024-06-24 | 에벨로 바이오사이언시즈, 인크. | 박테리아 및 미생물 세포외 소포를 함유하는 고체 투여 형태 |
| WO2023114300A1 (en) | 2021-12-14 | 2023-06-22 | Evelo Biosciences, Inc. | Fournierella massiliensis bacteria extracellular vesicle preparations |
| WO2023114295A1 (en) | 2021-12-14 | 2023-06-22 | Evelo Biosciences, Inc. | Veillonella parvula bacteria extracellular vesicle preparations |
| WO2023114296A2 (en) | 2021-12-14 | 2023-06-22 | Evelo Biosciences, Inc. | Extracellular vesicle preparations |
| WO2023146843A1 (en) | 2022-01-25 | 2023-08-03 | Evelo Biosciences, Inc. | Extracellular vesicle compositions and methods of use |
| WO2023183396A1 (en) | 2022-03-22 | 2023-09-28 | Evelo Biosciences, Inc. | Compositions and methods of treating inflammation using prevotella histicola |
| WO2023200837A1 (en) | 2022-04-13 | 2023-10-19 | Evelo Biosciences, Inc. | Compositions and methods of treating inflammation using prevotella histicola |
| WO2023239728A1 (en) | 2022-06-07 | 2023-12-14 | Evelo Biosciences, Inc. | Compositions and methods of treating inflammation using prevotella histicola extracellular vesicles |
| WO2024102226A1 (en) | 2022-10-14 | 2024-05-16 | Evelo Biosciences, Inc. | Methods for assaying drug substances and drug products by using cell lines with nf-kb- inducible reporter genes |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4994260A (en) | 1982-05-28 | 1991-02-19 | Astra Lakemedel Aktiebolag | Pharmaceutical mixture |
| US5238686A (en) | 1986-03-27 | 1993-08-24 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
| US4968508A (en) | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
| US5540945A (en) * | 1989-05-11 | 1996-07-30 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines |
| EP0418565B1 (en) * | 1989-09-21 | 1994-11-30 | American Cyanamid Company | Pulsatile once-a-day delivery system for minocycline |
| WO1991006281A1 (fr) * | 1989-10-26 | 1991-05-16 | Nippon Shinyaku Co., Ltd. | Preparation gastrique |
| US5229131A (en) | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
| US5188836A (en) * | 1990-07-27 | 1993-02-23 | Warner-Lambert Company | Sustained release formulations |
| US5102668A (en) | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
| US5286493A (en) | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
| DE19630035A1 (de) * | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
| US5885616A (en) * | 1997-08-18 | 1999-03-23 | Impax Pharmaceuticals, Inc. | Sustained release drug delivery system suitable for oral administration |
| US5968554A (en) * | 1998-07-07 | 1999-10-19 | Cascade Development, Inc. A Subsidiary Of Cardinal Health, Inc. | Sustained release pharmaceutical preparation |
-
1999
- 1999-06-23 US US09/338,716 patent/US6312728B1/en not_active Expired - Lifetime
- 1999-06-25 AU AU50842/99A patent/AU5084299A/en not_active Abandoned
- 1999-06-25 DE DE69919713T patent/DE69919713T2/de not_active Expired - Lifetime
- 1999-06-25 ES ES99935347T patent/ES2226412T3/es not_active Expired - Lifetime
- 1999-06-25 EP EP99935347A patent/EP1094790B9/en not_active Expired - Lifetime
- 1999-06-25 IL IL14076199A patent/IL140761A0/xx unknown
- 1999-06-25 AT AT99935347T patent/ATE274344T1/de not_active IP Right Cessation
- 1999-06-25 WO PCT/US1999/014204 patent/WO2000001369A1/en not_active Ceased
- 1999-06-25 JP JP2000557816A patent/JP2003524592A/ja active Pending
- 1999-06-25 CA CA002337046A patent/CA2337046C/en not_active Expired - Lifetime
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007507491A (ja) * | 2003-09-29 | 2007-03-29 | シージェー コーポレーション | 徐放性製剤 |
| JP2007519741A (ja) * | 2004-01-29 | 2007-07-19 | ヤマノウチ・ファーマ・テクノロジーズ・インク | 胃腸特異的複数薬物放出システム |
| JP2008509193A (ja) * | 2004-08-13 | 2008-03-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | プラミペキソール又はその薬学的に許容しうる塩を含有する徐放性ペレット製剤、その製法及び使用 |
| KR101443943B1 (ko) * | 2007-05-07 | 2014-10-07 | 에보니크 룀 게엠베하 | 가속된 약물 방출을 갖는 장용 코팅을 포함하는 고체 투여 형태 |
| US9597293B2 (en) | 2007-05-07 | 2017-03-21 | Evonik Röhm Gmbh | Solid dosage forms comprising an enteric coating with accelerated drug release |
| US10537530B2 (en) | 2007-05-07 | 2020-01-21 | Evonik Operations Gmbh | Solid dosage forms comprising an enteric coating with accelerated drug release |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1094790A1 (en) | 2001-05-02 |
| DE69919713T2 (de) | 2005-09-22 |
| ATE274344T1 (de) | 2004-09-15 |
| IL140761A0 (en) | 2002-02-10 |
| EP1094790B9 (en) | 2005-05-04 |
| WO2000001369A1 (en) | 2000-01-13 |
| DE69919713D1 (de) | 2004-09-30 |
| CA2337046A1 (en) | 2000-01-13 |
| AU5084299A (en) | 2000-01-24 |
| CA2337046C (en) | 2005-08-16 |
| US6312728B1 (en) | 2001-11-06 |
| EP1094790B1 (en) | 2004-08-25 |
| ES2226412T3 (es) | 2005-03-16 |
| EP1094790A4 (en) | 2003-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003524592A (ja) | 持続放出薬物製剤 | |
| US5968554A (en) | Sustained release pharmaceutical preparation | |
| EP0642335B2 (en) | Controlled release preparation containing a salt of morphine | |
| AU2002330211B2 (en) | Timed, sustained release multi-particulate dosage forms of propranolol | |
| US5411745A (en) | Powder-layered morphine sulfate formulations | |
| US7544372B2 (en) | Modified release dosage forms of skeletal muscle relaxants | |
| US6077533A (en) | Powder-layered oral dosage forms | |
| US9040086B2 (en) | Timed, sustained release systems for propranolol | |
| US20030161874A1 (en) | Controlled release oral dosage form | |
| JP2003508430A (ja) | トラマドールサッカリナートを含有する徐放性投薬形 | |
| JP2003503341A (ja) | 少なくとも一つの適時パルスを生ずる制御された放出用の医薬投与形態 | |
| AU2002330211A1 (en) | Timed, sustained release multi-particulate dosage forms of propranolol | |
| HUE029680T2 (en) | Dispensing systems containing weakly basic active ingredients and organic acids | |
| HU227490B1 (en) | Sustained release pharmaceutical preparation containing carvedilol | |
| US8642078B2 (en) | Coated formulations for tolterodine | |
| CA2433915C (en) | Improved controlled release oral dosage form | |
| KR20090128918A (ko) | 염산 알푸조신이 함유된 서방형 제제의 제조 | |
| JP2003507416A (ja) | 医薬製剤 | |
| MXPA01000205A (en) | Sustained release pharmaceutical preparation | |
| AU2002253907A1 (en) | Improved controlled release oral dosage form | |
| MX2008009613A (en) | Drug delivery systems comprising weakly basic drugs and organic acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050325 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050624 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050926 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051003 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051110 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20051110 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060310 |